The Hydroponics Company Ltd’s (ASX:THC) vertically integrated ‘farm to pharma’ medicinal cannabis strategy will be outlined during the Proactive CEO Session in Sydney on Monday, October 22.
The company’s Medicinal Cannabis Division lead Andrew Beehag will make the presentation to investors.
He will also explain the reasons for the company’s intended name change to THC Global Group Limited.
This will be one of 14 resolutions put to shareholders to vote on at the company’s annual general meeting on November 15, 2018.
THC’s strategy begins with a growing site in northern New South Wales and a growing, research and development facility in Queensland.
It flows through to an industry-leading biopharmaceutical manufacturing facility ready for pharma-grade production.
THC also has established international commercial partnerships with global industry leaders across Europe, Middle East, North America and Australia.
Beehag will also outline the company’s near-term plans to complete licensing and permitting activities on existing facilities and expand its product distribution.
He has been associated with the company from its inception in 2016, including its successful licensing and partnership alliancing with Endoca and BOL Pharma.
As a key part of the team, he has helped build THC’s successful investment and partnership strategy, gearing up THC to supply to domestic patients and the export market.
Register for the CEO Session today to find out more.